dabigatran has been researched along with fingolimod hydrochloride in 2 studies
| Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) |
|---|---|---|---|---|---|
| 3,887 | 261 | 3,490 | 2,771 | 157 | 2,062 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hussar, DA | 1 |
| Furberg, CD; Moore, TJ | 1 |
2 other study(ies) available for dabigatran and fingolimod hydrochloride
| Article | Year |
|---|---|
New drugs 2011 part 2.
Topics: Benzimidazoles; Contraceptives, Postcoital; Dabigatran; Drug Therapy; Fibrinolytic Agents; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Norpregnadienes; Pharmaceutical Preparations; Propylene Glycols; Pyridines; Sphingosine | 2011 |
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Topics: Anticoagulants; Antineoplastic Agents; Benzimidazoles; beta-Alanine; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Dabigatran; Drug Approval; Efficiency, Organizational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Patient Safety; Piperidines; Propylene Glycols; Quinazolines; Risk; Sphingosine; Stroke; Thyroid Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2012 |